90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials
OBJECTIVES/GOALS: Childhood Sjögren’s disease (cSD) is a rare autoimmune disease. Despite the profound impact on children and their families, pediatric-specific clinical trials to inform therapeutic strategies in cSD are lacking. In 2022 we participated in the Trial Innovation Network (TIN) Design L...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2024-04-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866124000888/type/journal_article |
| _version_ | 1797226898888065024 |
|---|---|
| author | Nora G. Singer Sara M Stern Marisha E Palm Harry Selker Ludovic Trinquart |
| author_facet | Nora G. Singer Sara M Stern Marisha E Palm Harry Selker Ludovic Trinquart |
| author_sort | Nora G. Singer |
| collection | DOAJ |
| description | OBJECTIVES/GOALS: Childhood Sjögren’s disease (cSD) is a rare autoimmune disease. Despite the profound impact on children and their families, pediatric-specific clinical trials to inform therapeutic strategies in cSD are lacking. In 2022 we participated in the Trial Innovation Network (TIN) Design Lab with the purpose of designing a series of N-of-1 trials for cSD. METHODS/STUDY POPULATION: New medications have the potential to be safe/effective treatments for cSD but must be evaluated in randomized trials. To overcome limitations of traditional parallel-group designs given the rarity of cSD, we developed an N-of-1 trial approach. Our proposal was selected by the Tufts TIN Design Lab. The Design Lab multi-stakeholder process involved parents of and patients with cSD, pediatric and adult rheumatologists, and experts in clinical trial design and outcomes. We engaged all stakeholders in protocol development to maximize the impact of the proposed approach on clinical care, ensure a successful recruitment plan, and inform the choice of endpoints as there are no widely accepted cSD outcome measures to determine treatment efficacy. RESULTS/ANTICIPATED RESULTS: Using the Design Lab methodology, we clarified the N-of-1 study goals and engaged in an iterative process to develop a “briefing book” that ensured a sound premise for our study. We reviewed and accumulated published literature to support our focus on mucosal/glandular manifestations, identified potential interventions to be used in the N-of-1 trials, and enumerated possible outcomes, including outcomes important to patient/parents. This work culminated in a full-day Design Lab event that included multiple stakeholders who provided expertise from different perspectives on the full drug development pathway. Study design feedback focused on three specific areas. 1) Inclusion and exclusion criteria; 2) Identification of outcome measures; 3) Treatment and washout periods. DISCUSSION/SIGNIFICANCE: To address the critical need and move treatment of cSD forward, we are designing a prototype N-of-1 trial in children with rheumatic disease. We will continue to engage stakeholders by using a series of Delphi surveys and an in-person meeting to create composite outcome measures to test cSD therapies in personalized trials. |
| first_indexed | 2024-04-24T14:32:14Z |
| format | Article |
| id | doaj.art-944f1b6844c74377a7cfed6fc286ae68 |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-24T14:32:14Z |
| publishDate | 2024-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-944f1b6844c74377a7cfed6fc286ae682024-04-03T02:00:15ZengCambridge University PressJournal of Clinical and Translational Science2059-86612024-04-018242410.1017/cts.2024.8890 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trialsNora G. Singer0Sara M Stern1Marisha E Palm2Harry Selker3Ludovic Trinquart4CWRU MetroHealth CampusUniversity of UtahTufts UniversityTufts UniversityTufts UniversityOBJECTIVES/GOALS: Childhood Sjögren’s disease (cSD) is a rare autoimmune disease. Despite the profound impact on children and their families, pediatric-specific clinical trials to inform therapeutic strategies in cSD are lacking. In 2022 we participated in the Trial Innovation Network (TIN) Design Lab with the purpose of designing a series of N-of-1 trials for cSD. METHODS/STUDY POPULATION: New medications have the potential to be safe/effective treatments for cSD but must be evaluated in randomized trials. To overcome limitations of traditional parallel-group designs given the rarity of cSD, we developed an N-of-1 trial approach. Our proposal was selected by the Tufts TIN Design Lab. The Design Lab multi-stakeholder process involved parents of and patients with cSD, pediatric and adult rheumatologists, and experts in clinical trial design and outcomes. We engaged all stakeholders in protocol development to maximize the impact of the proposed approach on clinical care, ensure a successful recruitment plan, and inform the choice of endpoints as there are no widely accepted cSD outcome measures to determine treatment efficacy. RESULTS/ANTICIPATED RESULTS: Using the Design Lab methodology, we clarified the N-of-1 study goals and engaged in an iterative process to develop a “briefing book” that ensured a sound premise for our study. We reviewed and accumulated published literature to support our focus on mucosal/glandular manifestations, identified potential interventions to be used in the N-of-1 trials, and enumerated possible outcomes, including outcomes important to patient/parents. This work culminated in a full-day Design Lab event that included multiple stakeholders who provided expertise from different perspectives on the full drug development pathway. Study design feedback focused on three specific areas. 1) Inclusion and exclusion criteria; 2) Identification of outcome measures; 3) Treatment and washout periods. DISCUSSION/SIGNIFICANCE: To address the critical need and move treatment of cSD forward, we are designing a prototype N-of-1 trial in children with rheumatic disease. We will continue to engage stakeholders by using a series of Delphi surveys and an in-person meeting to create composite outcome measures to test cSD therapies in personalized trials.https://www.cambridge.org/core/product/identifier/S2059866124000888/type/journal_article |
| spellingShingle | Nora G. Singer Sara M Stern Marisha E Palm Harry Selker Ludovic Trinquart 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials Journal of Clinical and Translational Science |
| title | 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials |
| title_full | 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials |
| title_fullStr | 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials |
| title_full_unstemmed | 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials |
| title_short | 90 Novel approach for childhood Sjögren’s Disease therapies: multistakeholder design of a series of N-of-1 trials |
| title_sort | 90 novel approach for childhood sjogren s disease therapies multistakeholder design of a series of n of 1 trials |
| url | https://www.cambridge.org/core/product/identifier/S2059866124000888/type/journal_article |
| work_keys_str_mv | AT noragsinger 90novelapproachforchildhoodsjogrensdiseasetherapiesmultistakeholderdesignofaseriesofnof1trials AT saramstern 90novelapproachforchildhoodsjogrensdiseasetherapiesmultistakeholderdesignofaseriesofnof1trials AT marishaepalm 90novelapproachforchildhoodsjogrensdiseasetherapiesmultistakeholderdesignofaseriesofnof1trials AT harryselker 90novelapproachforchildhoodsjogrensdiseasetherapiesmultistakeholderdesignofaseriesofnof1trials AT ludovictrinquart 90novelapproachforchildhoodsjogrensdiseasetherapiesmultistakeholderdesignofaseriesofnof1trials |